poster

AACR 2023: Evaluation of a 293 gene oncology-focused exome sequencing panel for screening of ovarian cancer patients for BRCA mutations as a rerequisite for manufacturing of an autologous cellular immunotherapy

Frontage Genomics Services has validated a custom-designed 293 cancer-related genes panel. A key application is the determination of BRCA1/2 mutation status to qualify for a personalized treatment called Gemogenovatucel-T, a cellular immunotherapy that improves recurrence-free and overall survival only in ovarian cancer patients with no mutations in BRCA1/2 genes. This panel enables rapid analysis of genomic DNA from blood using hybridization-based library preparation, sequencing on the Illumina NextSeq2000 platform and accurate screening with full coverage of BRCA1/2 exons and adjacent introns. This panel is also capable of detecting somatic variants with high sensitivity of up to 3% allele fraction, supporting biomarker discovery, cancer biology research and drug development.